June 2012 
Volume 42  Number 6
Pages 10 - 10
  PDF Version Available!

Brodalumab (AMG 827), a human anti-interleukin-17-receptor monoclonal antibody, was recently tested for safety and efficacy for treating moderate-to-severe plaque psoriasis. Patients with a score of 12 or higher on the psoriasis area and severity index (PASI) and with 10% or more of their body surface area affected by psoriasis were randomly assigned to receive either brodalumab or a placebo. The primary end point of this study was to improve baseline PASI percentages.At week 12, the mean percentage improvements in the PASI score were 45% among patients receiving 70 mg of brodalumab, 85.9% for those receiving 140 mg, and 86.3% for those receiving 210 mg. The placebo group had a 16% mean improvement score. Researchers concluded that brodalumab significantly improved plaque psoriasis during this 12-week phase II trial study, conducted to determine common, short-term adverse reactions and risks in patients with plaque psoriasis.Source: Papp KA, Leonardi C, Menter A, et al. Brodalumab, an

Purchase Now !

To purchase this item, follow the instructions below. If you’re not already logged in, be sure to enter your login information below to ensure that your item is saved to your File Drawer after you purchase it.

Not a member? Join now for Free!

1) If you're not already logged in, enter your information below to save this item in your File Drawer for future viewing.

User name:


Forgot your user name or password?
2)  If you have a coupon or promotional code, enter it
here.(If not, just click Continue.

Digital Coupon: (optional)

3)  Click Continue to go to the next screen, where
you'll enter your payment details.

jQuery UI Accordion - Default functionality

For life-long learning and continuing professional development, come to Lippincott's NursingCenter.

Nursing Jobs Plus
Featured Jobs
Recommended CE Articles Recommended Nursing Articles Evidence Based Practice Skin Care Network NursingCenter Quick Links What’s Trending Events